The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)

Published:2017-04 Issue: Volume:392 Page:9-16
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Gazi Mohiuddin,Moharram Sausan A.,Marhäll Alissa,Kazi Julhash U.^ORCID

Funder

Kungliga Fysiografiska Sällskapet i Lund

Per-Eric och Ulla Schybergs stiftelse

Ollie and Elof Ericssons Stiftelse

Stiftelsen Thelma Zoégas

the Crafoord Foundation

Stiftelsen Clas Groschinskys Minnesfond

Swedish Childhood Cancer Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J. Clin.,2013

2. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway;Lonetti;J. Hematol. Oncol.,2016

3. T-cell acute lymphoblastic leukaemia: recent molecular biology findings;Kraszewska;Br. J. Haematol.,2012

4. The molecular basis of T cell acute lymphoblastic leukemia;Van Vlierberghe;J. Clin. Invest,2012

5. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability;Silva;J. Clin. Invest,2008

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma;Biomedicines;2024-07-19

3. The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies;Expert Review of Anticancer Therapy;2024-05-08

4. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track?;Current Medicinal Chemistry;2024-04-04

5. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities;Cancers;2023-11-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3